Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
ELUT is expected to report earnings to fall 23.53% to -12 cents per share on November 16
Q3'26
Est.
$-0.13
Q2'26
Missed
by $0.02
Q1'26
Missed
by $0.02
Q4'25
Beat
by $1.60
Q3'25
Missed
by $0.04
The last earnings report on August 13 showed earnings per share of -17 cents, missing the estimate of -15 cents. With 956.00 shares outstanding, the current market capitalization sits at 42.11M.